Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
Benitec Biopharma Inc.NASDAQ: BNTC
Effect of Forex Changes · Q3 FY2026 · quarter ended Mar 2026
Effect of forex changes growth accelerates
Q3 FY2026 effect of forex changes of $3.46M (cash outflow) rose 16371.5% year over year, ahead of the -3175.5% change in trailing-twelve-month effect of forex changes. Sequentially, it rose 2520.5% from the prior quarter. Over 3 fiscal years it compounded at -37.8% a year.
Context
- Effect of forex changes increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +16371.5% holds above the trailing-twelve-month pace of -3175.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
USD · from the cash flow
- Latest · FY2025
- 49K USD
- Year-over-year change
- +712.5%
- 4-year CAGR
- -44.0%
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 49K | +712.5% |
| FY2024 | 2024-06-30 | (8K) | -101.9% |
| FY2023 | 2023-06-30 | 412K | +102.0% |
| FY2022 | 2022-06-30 | 204K | -59.1% |
| FY2021 | 2021-06-30 | 499K | — |
Effect of Forex Changes vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's LTM Mar 2026 effect of forex changes of $5.04M is the 2nd largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -3175.5% is the lowest of 7, against a peer median of +235.7%.
- Over three fiscal years its annual growth of -37.8% compares with a peer median of -19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.64M | -1479.4% | — | 98.4% | |
| LTM Mar 2026 | $5.04M | -3175.5% | -37.8% | — | |
| LTM Mar 2026 | $1.36M | — | — | — | |
| LTM Mar 2026 | $732K | -83.7% | — | 0.8% | |
| LTM Mar 2026 | $460K | +569.4% | — | 3.1% | |
| LTM Mar 2026 | $121K | +706.7% | -19.6% | 2.7% | |
| LTM Mar 2026 | $66K | +371.4% | — | 3.6% | |
| FY2025 | $19.83K | — | — | 0.4% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding BNTC) | $0 | +235.7% | -19.6% | 2.9% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| Deferred Income Tax | 0 | 0 | (714K) | 0 | 0 |
| Stock-Based Compensation | 634K | 870K | 452K | 830K | 17.43M |
| Change in Working Capital | 8K | 1.04M | 714K | 1.17M | (2.73M) |
| Accounts Receivables | 28K | 1K | (50K) | (176K) | 197K |
| Inventory | (83K) | (1.09M) | (1.31M) | 0 | 0 |
| Accounts Payables | 55K | 1.09M | 1.36M | 0 | (2.38M) |
| Other Working Capital | 8K | 1.04M | 714K | 1.35M | (548K) |
| Other Non-Cash Items | (16K) | 10K | 717K | 1K | (764K) |
| Operating Cash Flow | (12.83M) | (15.9M) | (18.01M) | (19.4M) | (23.59M) |
| Capital Expenditures | (221K) | (13K) | (1K) | (179K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (221K) | (13K) | (1K) | (179K) | (18K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.75M | 0 | 17.88M | 70.88M | 70.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | 0 | (1.87M) | (2.85M) | 0 |
| Financing Cash Flow | 22.52M | 0 | 16.02M | 68.03M | 70.49M |
| Effect of Forex Changes | 499K | 204K | 412K | (8K) | 49K |
| Net Change in Cash | 9.97M | (15.71M) | (1.59M) | 48.44M | 46.93M |
| Free Cash Flow | (13.05M) | (15.91M) | (18.01M) | (19.58M) | (23.61M) |
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.